Biogen: latest news - GoINPHARMA
Monday, 22 October 2018 - 9:00

Biogen

Biogen to pay $600m for Pfizer-developed schizophrenia therapy

Biogen yesterday announced it has acquired from Pfizer the rights to the investigational PF-04958242 therapy, developed to treat some symptoms of schizophrenia, a condition affecting over 20 million people globally. As part of the agreement, Biogen will make Pfizer an…

Why big pharma companies always create new spinoffs

The recent acquisitions in the pharma sector (Sanofi, Celgene, Biogen) have confirmed that the strategy adopted by many groups–i.e. spinning off part of their assets and divesting them–is the best way to grant shareholders a rich financial return. The most…

Biogen announces quarter results exceeding expectations and shares soar

The fiscal reform introduced by the Trump Administration has given impetus to a new, incredible M&A season in the US pharma sector. Biotech company Biogen today has announced it has acquired for $217m Karyopharm’s investigational therapy KPT-350, for the treatment…

Biogen and UCB targeting Acorda Therapeutics (€1bn)

US-based Acorda Therapeutics (New York) is reportedly targeted by Belgium-based UCB, the Belgian daily De Tijd has reported today. Acorda Therapeutics is worth approximately $1bn, according to analysts (Bloomberg). Due to pressure by shareholders, Acorda’s management in August put the…

Hopes for Alzheimer’s therapy focus on Biogen (aducanumab)

Academia and investors were dejected as Pfizer last week announced it would end research for Alzheimer’s treatments. The few multinationals still working on Alzheimer’s – Eli Lilly, Biogen and Novartis – have recently said they are determined to keep funding…

Gloomy results from the research for an Alzheimer’s therapy

Alzheimer’s is a pathology affecting 44 million people globally, with an extremely high social cost, which – for example – is close to $249bn pa in the US. Only four approved therapies are currently available to ease the effects of…

NEJM publishes Phase III results for Biogen/Ionis’ Spinraza

Biogen and Ionis Pharmaceuticals have announced that final results from the Phase III clinical trial ENDEAR, aimed at assessing Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA) have been published in the New England Journal of Medicine (NEJM)….

New terms for Biogen/Eisai agreement

Eisai Co. and Biogen Inc. have announced they have extended their already existing collaboration agreement to develop and market new Alzheimer’s treatments. Under the terms of the agreement, Eisai has exercised its option to jointly develop and commercialize aducanumab, Biogen’s…

Alzheimer’s: Ionis Initiates phase I/II trial for antisense drug

Ionis Pharmaceuticals has initiated its Phase I//IIa clinical trial designed to test IONIS-MAPTRx in patients with moderate Alzheimer’s disease. Having initiated this study, Ionis will receive a $10m milestone payment from Biogen. IONIS-MAPTRx is an antisense drug designed to selectively…

Alzheimer, significant results for Biogen’s aducanumab

Biogen today announced the results from an analysis of the long-term extension of its Phase Ib randomized, double-blind, placebo-controlled study of aducanumab, the investigational treatment for early Alzheimer’s disease. The new data include results from patients treated with aducanumab up…

Biogen’s Imraldi, biosimilar to Humira, approved in Europe

Biogen has announced that the European Commission has approved Imraldi, a biosimilar to Humira. The drug has been co-developed by a Biogen-Samsung Bioepis joint venture. It has been approved for the treatment of rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis…

Biogen/AbbVie’s Zinbryta under review by PRAC

EMA PRAC (Pharmacovigilance Risk Assessment Committee) launched a review of Biogen/AbbVie’s Zinbryta (daclizumab). The product is intended to treat adult patients with relapsing forms of multiple sclerosis. The review follows the sudden death from liver failure of a patient who…

Biogen strengthens position in neurology business through $120m acquisition

US-based biotech company Biogen today announced it purchased the rights to investigational drug Cirara from Remedy Pharmaceuticals for $120m. Cirara (intravenous glyburide) is a treatment of ischemic stroke, specifically of a form called LHI (large hemispheric infarction), which affects approximately…

CHMP: OK to Biogen’s Spinraza for SMA

Biogen has announced that EMA CHMP has adopted a positive opinion on Spinraza (nusinersen) for the treatment of SMA (spinal muscular atrophy). The Agency has reviewed the product under its accelerated assessment program, designed to facilitate access to medicines likely…

UnitedHealthcare to cover Biogen/Ionis’ Spinraza

According to an update by UnitedHealthcare, the company will cover Spinraza (nusinersen) for patients with SMA (spinal muscular atrophy) types 1-3, Bloomberg reported. The drug is produced by Biogen and Ionis Pharmaceuticals. The policy specifies that Spinraza should be prescribed…

2016 results from seven companies expected next week

BioPharmaDive has provided an interesting report of what we can expect from the pharma and biotech companies which will report their results next week. Such remarks are significant, especially following declarations by the US President-elect. As for Johnson & Johnson,…

Biogen’s Spinraza, positive data in SMA

Biogen presented new data from the Phase III ENDEAR study of Spinraza (nusinersen), which demonstrated a significant reduction in the risk of death or permanent ventilation in infants with SMA (spinal muscular atrophy) treated with Spinraza vs the untreated group….

Time to be listed for Biogen’s spin-off Bioverativ

Biogen announced that NASDAQ authorities have given the green light to the quotation of its spin-off Bioverativ. Bioverativ, founded last December 20th, operates in the treatment areas of hemophilia and other rare blood disorders. The company is currently marketing two…

The pipelines of the groups working on Alzheimer’s treatments

Following the recently announced failure of Eli Lilly’s clinical trial, many analysts are drawing up new rankings of the pipelines of the most active groups in the Alzheimer’s treatment area. Germany-based biotech Probiodrug is focused on a research branch aimed…

FDA approves Biogen’s Spinraza, first treatment for SMA

FDA approved Biogen’s Spinraza (nusinersen) under Priority Review for the treatment of SMA (Spinal Muscular Atrophy) in pediatric and adult patients. The product, to be administered via intrathecal injection, is the first and only treatment approved in the US for…